Provided by Tiger Trade Technology Pte. Ltd.

Fidelity MSCI Health Care Index ETF

81.30
0.0000
Post-market: 81.300.00000.00%16:15 EDT
Volume:238.72K
Turnover:19.47M
Market Cap:3.54B
PE:- -
High:81.85
Open:81.38
Low:81.12
Close:81.30
52wk High:85.46
52wk Low:64.30
Shares:43.50M
Float Shares:43.50M
Volume Ratio:0.46
T/O Rate:0.55%
Dividend:1.02
Dividend Rate:1.25%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

J&J EVP, Worldwide Chair MedTech Timothy Schmid Disposes of 33,597 Common Shares Worth $9.23 Million

Reuters
·
Sep 04

Dow Jones Top Company Headlines at 9 am ET: EQT to Buy Insurance Broker McGill in $2 Billion Deal | Tesla-Challenging ...

Dow Jones
·
Sep 04

Scotiabank Remains a Buy on AbbVie (ABBV)

TIPRANKS
·
Sep 04

UnitedHealth (UNH) Gets a Buy from Bernstein

TIPRANKS
·
Sep 04

Wells Fargo Adjusts Price Target on Merck & Co. to $170 From $150, Keeps Overweight Rating

MT Newswires Live
·
Sep 04

AbbVie Closes $10.9B Takeover of Apogee, Its Largest Deal Since 2019, With Earnings Lift Expected From 2032

Stock News
·
Sep 04

Perrigo Co. PLC Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Sep 04

Eli Lilly Stock (LLY) Gets a Bullish Note from JPMorgan Chase

TIPRANKS
·
Sep 04

Sector Update: Healthcare Stocks Higher Thursday Afternoon

MT Newswires Live
·
Sep 04

Healthcare Stocks Pick up Steam as Investors Play Offense and Defense

Dow Jones
·
Sep 04

Eisai’s Lenvima Combo Trial in Liver Cancer Ends With Mixed but Market-Relevant Results

TIPRANKS
·
Sep 04

Summit Therapeutics Says it is Beating Merck with Its Cancer Drug

Dow Jones
·
Sep 04

AbbVie's Phase 3 Study of Etentamig in Multiple Myeloma Meets Dual Primary Endpoints

MT Newswires Live
·
Sep 03

AbbVie Says Blood Cancer Drug Met Dual Primary Endpoints in Phase 3 Study

Dow Jones
·
Sep 03

AbbVie announces Phase 3 Cervino study met dual primary endpoints of ORR, PFS

TIPRANKS
·
Sep 03

AbbVie's Blood Cancer Drug Meets Late-Stage Trial Goals

Reuters
·
Sep 03

Abbvie - Phase 3 Cervino Study Met Dual Primary Endpoints; Full Results to be Presented Sept 23-26

THOMSON REUTERS
·
Sep 03

Abbvie - Etentamig Demonstrates Low Rates of Cytokine Release Syndrome and Fatal Infections

THOMSON REUTERS
·
Sep 03

Abbvie - Etentamig Achieves 74% Orr and 60% Risk Reduction in Phase 3 Cervino Trial

THOMSON REUTERS
·
Sep 03

Abbvie Announces Positive Topline Results from the Phase 3 Cervino Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma

THOMSON REUTERS
·
Sep 03